A detailed history of Abound Wealth Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Abound Wealth Management holds 92 shares of VRTX stock, worth $37,779. This represents 0.01% of its overall portfolio holdings.

Number of Shares
92
Previous 94 2.13%
Holding current value
$37,779
Previous $43.9 Million 2.89%
% of portfolio
0.01%
Previous 0.02%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$460.0 - $505.78 $920 - $1,011
-2 Reduced 2.13%
92 $42.7 Million
Q1 2024

Aug 08, 2024

BUY
$407.69 - $446.08 $407 - $446
1 Added 1.08%
94 $39.2 Million
Q4 2023

Aug 08, 2024

BUY
$343.0 - $410.68 $14,749 - $17,659
43 Added 86.0%
93 $37.8 Million
Q3 2023

Aug 08, 2024

BUY
$338.18 - $362.46 $1,014 - $1,087
3 Added 6.38%
50 $17.4 Million
Q2 2023

Aug 08, 2024

BUY
$314.42 - $351.91 $3,458 - $3,871
11 Added 30.56%
47 $16.5 Million
Q1 2023

Aug 07, 2024

BUY
$283.23 - $323.1 $10,196 - $11,631
36 New
36 $11.3 Million
Q4 2022

Aug 07, 2024

BUY
$285.76 - $321.48 $4,286 - $4,822
15 Added 100.0%
30 $8.66 Million
Q3 2022

Aug 07, 2024

SELL
$273.83 - $305.53 $5,750 - $6,416
-21 Reduced 58.33%
15 $4.34 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Abound Wealth Management Portfolio

Follow Abound Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abound Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Abound Wealth Management with notifications on news.